Chloramphenicol
FDA-approved product (solution/drops, ophthalmic), marketed as Chloramphenicol, Chlorofair, Chloromycetin and 5 more.
- Registered studies
- 23
- Lab records
- 42
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Acne
- Bacterial disease
- Eye infection
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Other antibiotics for topical use; Antiinfectives for treatment of acne; Antibiotics; Amphenicols; Antiinfectives
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC D10AF03; WHO ATC J01BA01; WHO ATC D06AX02; WHO ATC G01AA05; WHO ATC S01AA01
Repurposing investigation
Chloramphenicol is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA30.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli36.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae14.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis27.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
23registered studies name this medicine, for any condition. See them below.
Experimental
- MRSA: measured active in 0 of 3 lab records
- E. coli: measured active in 2 of 2 lab records
- K. pneumoniae: measured active in 21 of 37 lab records
Show the 42 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Chloramphenicol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Ozanimod HydrochlorideExisting use: Multiple sclerosis, Relapsing-remitting multiple sclerosis, Ulcerative colitis66.8% AI-predicted activityagainst MRSA7 registered studies
- Micafungin SodiumExisting use: Candidiasis66.8% AI-predicted activityagainst MRSA50+ registered studies
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- Lazertinib MesylateExisting use: Non-small cell lung carcinoma66.1% AI-predicted activityagainst MRSANo documented evidence found
- Desmopressin AcetateExisting use: Central diabetes insipidus, Diabetes insipidus, Enuresis and 5 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia65.8% AI-predicted activityagainst MRSA41 registered studies
- VemurafenibExisting use: Cancer, Cutaneous melanoma, Melanoma and 2 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more65.5% AI-predicted activityagainst MRSA50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm65.5% AI-predicted activityagainst MRSA50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more65.4% AI-predicted activityagainst MRSA5 registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more65.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
The Efficacy of Permethrin 5%, Fusidic Acid 1% and Synthomycine 5% for Demodex - Blepharitis
NCT03105505 · start 2017-04-28
Registered record
- Registry ID
- NCT03105505
- Conditions
- Inflammation of the Eyelids
- Interventions
- Permethrin 5%; Synthomycine 5%; Fusidic Acid 1% M/R Eye Drops
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2017-04-28
- Completion
- 2018-09
- Enrolment
- 75
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInflammation of the EyelidsInterventionPermethrin 5%; Synthomycine 5%; Fusidic Acid 1% M/R Eye DropsPhasePhase 4Registry statusUnknownPatients Response to Early Switch To Oral:Osteomyelitis Study
NCT02099240 · start 2014-03-06
Registered record
- Registry ID
- NCT02099240
- Conditions
- Osteomyelitis
- Interventions
- oral antibiotics; intravenous antibiotics
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Terminated
- Start
- 2014-03-06
- Completion
- 2018-11-07
- Enrolment
- 11
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteomyelitisInterventionoral antibiotics; intravenous antibioticsPhaseEarly phase 1Registry statusTerminatedVillage Integrated Eye Workers Trial
NCT01969786 · start 2014-02
Registered record
- Registry ID
- NCT01969786
- Conditions
- Corneal Ulcer
- Interventions
- Corneal ulcer prevention program
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2014-02
- Completion
- 2021-03
- Enrolment
- 223,671
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCorneal UlcerInterventionCorneal ulcer prevention programPhaseNot applicableRegistry statusCompletedAlcohol 20% for Separation of Pterygium and Comparison of Different Wound Closure Methods
NCT00704977 · start 2008-06
Registered record
- Registry ID
- NCT00704977
- Conditions
- Pterygium
- Interventions
- pterygium surgery using alcohol 20% for tissue separation and bare sclera as wound closure technique
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2008-06
- Completion
- 2010-07
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPterygiumInterventionpterygium surgery using alcohol 20% for tissue separation and bare sclera as wound closure techniquePhaseNot applicableRegistry statusUnknownEffect of Thiamphenicol on EAAT2 and Other Biomarkers From Nasal Biopsied Tissue
NCT00958503 · start 2007-07
Registered record
- Registry ID
- NCT00958503
- Conditions
- Healthy
- Interventions
- Thiamphenicol; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2007-07
- Completion
- 2008-04
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionThiamphenicol; PlaceboPhasePhase 1Registry statusCompletedCeftriaxone Versus Chloramphenicol for Treatment of Severe Pneumonia in Children
NCT00372541 · start 2006-09
Registered record
- Registry ID
- NCT00372541
- Conditions
- Pneumonia
- Interventions
- ceftriaxone
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-09
- Completion
- 2007-03
- Enrolment
- 348
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPneumoniaInterventionceftriaxonePhasePhase 3Registry statusCompletedAntimicrobial Pulpotomy of Primary Molars
NCT01010451 · start 2000-08
Registered record
- Registry ID
- NCT01010451
- Conditions
- Inflammation; Necrosis
- Interventions
- Antimicrobial pulpotomy; Calcium hydroxide pulpectomy
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2000-08
- Completion
- 2006-08
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInflammation; NecrosisInterventionAntimicrobial pulpotomy; Calcium hydroxide pulpectomyPhasePhase 4Registry statusCompletedThe Role of Umbilical Cord Serum Therapy on Improvement of Corneal Epithelial Defect Following Diabetic Vitrectomy
NCT01168375
Registered record
- Registry ID
- NCT01168375
- Conditions
- Corneal Epithelial Defect
- Interventions
- conventional therapy plus umbilical cord serum eye drop; conventional therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Unknown
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCorneal Epithelial DefectInterventionconventional therapy plus umbilical cord serum eye drop; conventional therapyPhasePhase 1Registry statusUnknown